Literature DB >> 2726274

Transdermal fentanyl for pain control in patients with cancer.

Angela W Miser1, Prem K Narang, Judith A Dothage, Robert C Young, William Sindelar, James S Miser.   

Abstract

Five cancer patients experienced satisfactory pain relief for periods of 3-156 days using continuous transdermal delivery of the narcotic fentanyl. The patients, aged 16-68 years, had all been experiencing pain and were either unable to take oral analgesic medications or these agents were ineffective in controlling pain. Doses were adjusted to individual patient needs and varied from 75 micrograms/h to 350 micrograms/h (median = 225 micrograms/h). Plasma fentanyl levels reflected the administered dose and remained constant throughout the treatment. Transdermal delivery of narcotics provides a new option for the cancer patient unable to achieve satisfactory analgesia with oral medications.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2726274     DOI: 10.1016/0304-3959(89)90148-6

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  19 in total

Review 1.  Novel drug delivery systems. An overview of their impact on clinical pharmacokinetic studies.

Authors:  P S Banerjee; J R Robinson
Journal:  Clin Pharmacokinet       Date:  1991-01       Impact factor: 6.447

2.  Fentanyl transdermal system. Pain management at home.

Authors:  M A Woodroffe; H Hays
Journal:  Can Fam Physician       Date:  1997-02       Impact factor: 3.275

Review 3.  Transdermal fentanyl. A review of its pharmacological properties and therapeutic efficacy in pain control.

Authors:  W Jeal; P Benfield
Journal:  Drugs       Date:  1997-01       Impact factor: 9.546

4.  Translating safety, efficacy and compliance into economic value for controlled release dosage forms.

Authors:  M P Cramer; S R Saks
Journal:  Pharmacoeconomics       Date:  1994-06       Impact factor: 4.981

5.  Six- versus 12-h conversion method from intravenous to transdermal fentanyl in chronic cancer pain: a randomized study.

Authors:  Motoo Nomura; Minoru Kamata; Hiroyuki Kojima; Kenji Hayashi; Masasuke Kozai; Satoshi Sawada
Journal:  Support Care Cancer       Date:  2010-06-13       Impact factor: 3.603

6.  Transdermal fentanyl for the treatment of pain after major urological operations. A randomized double-blind comparison with placebo using intravenous patient-controlled analgesia.

Authors:  K A Lehmann; C Einnolf; H J Eberlein; R Nagel
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 7.  Common emergencies in cancer medicine: cardiovascular and neurologic syndromes.

Authors:  C R Thomas; E A Edmondson
Journal:  J Natl Med Assoc       Date:  1991-11       Impact factor: 1.798

8.  Transdermal fentanyl in uncontrolled cancer pain: titration on a day-to-day basis as a procedure for safe and effective dose finding--a pilot study in 20 patients.

Authors:  W Korte; R Morant
Journal:  Support Care Cancer       Date:  1994-03       Impact factor: 3.603

9.  [Not Available].

Authors:  M Zenz
Journal:  Schmerz       Date:  1991-03       Impact factor: 1.107

10.  [Transdermal fentanyl for the treatment of cancer pain.].

Authors:  B Donner; M Zenz; M Tryba; M Strumpf
Journal:  Schmerz       Date:  1993-03       Impact factor: 1.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.